American pharmaceutical giant steering vaccines and medicines
A string of developments around testosterone replacement therapy (TRT) has sparked a national conversation. The US military is considering testing service members’ testosterone levels and expanding access to TRT where clinically appropriate, while lawmakers and experts weigh safety, ethics and performance implications. Reports from AP News, CNBC, CNBC and other outlets indicate a widening trend in how TRT is discussed and regulated.
The White House has convened a meeting with AI leaders to review a proposed cybersecurity framework for advanced models, following OpenAI's recent agent hacks and calls for greater government access. Attendees include executives from Hugging Face, Anthropic, and others; Meta and Alphabet may participate. Markets show mixed responses as investors watch the policy discussion unfold.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.
President Trump has signed an executive order directing federal health officials to cut the federal recommended childhood vaccine list, to split the combined MMR vaccine into separate measles, mumps and rubella doses once single‑disease products are available, and to space routine immunisations across separate medical visits. Public health groups and drugmakers have said the changes lack scientific support and will increase missed vaccinations during a major U.S. measles outbreak.
The Trump administration has urged states to separate the measles, mumps and rubella vaccine into individual shots. Several officials caution that doing so could fuel vaccine hesitancy and leave immunity gaps while some leaders push for more personal choice in immunization policies. New reporting shows the policy debate is unfolding amid mixed messages from health agencies and political leaders.
The Treasury has expanded its bond-buyback program to support longer-dated debt, but yields on the 10-year and 30-year Treasuries have remained elevated as debt levels and deficits draw scrutiny. Investors are weighing the impact on mortgages, AI infrastructure funding, and policy uncertainty across multiple outlets.
The FDA has approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with previously treated or ineligible metastatic pancreatic cancer. Clinical trials have shown median survival extended to about 13.2 months versus roughly 6.7 months with chemotherapy. The drug will be available in the US with a roughly $39,800 monthly list price and expanded-access programmes have already treated thousands.
Major US medical societies have issued unified guidance this week for flu, COVID-19 and RSV vaccines after the CDC’s advisory process has been disrupted. Updated COVID shots have FDA approval and manufacturers are shipping doses, but legal and policy disputes over federal recommendations continue to leave states and insurers uncertain about timing and coverage.
The White House has announced that most favored nation pricing will align U.S. drug prices with the lowest prices abroad, with several manufacturers set to participate. Officials say the move will lower costs for Americans and expand constraints on pricing practices.
Flu vaccines are underway and updated COVID-19 shots are arriving nationwide after FDA approval. RSV remains a threat, prompting guidance from medical societies as Trump health officials rethink autumn vaccine policies. An advisory panel remains in a legal dispute, while doctors push clear, science-based guidance. Older adults and high-risk groups are urged to vaccinate, with a new mRNA flu shot showing improved effectiveness.
The Justice Department has reached a settlement with Abbott over the Sturgis, Michigan plant that produced a major share of U.S. infant formula. The settlement addresses unsanitary conditions and recalls tied to Cronobacter sakazakii, while Abbott maintains no admission of fault. Regulators say the plant’s issues contributed to a nationwide shortage.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Documentary NAZA relies on anonymous Israeli military testimonials alleging AI-enabled targeting in Gaza. While the film has won Venice’s Special Jury Prize and will stream via The Guardian, Israeli officials deny the allegations and threaten legal steps against the filmmakers. The Guardian cooperates on distribution; filmmakers argue for public access amid ongoing debate.
The Federal Trade Commission and seven states have asked a federal judge to hold ex-pharma executive Martin Shkreli in contempt for allegedly violating a 2022 lifetime ban by trading pharmaceutical stocks and discussing the industry in livestreams since his release from prison.